Vaxcyte Plunges 13.26% Despite Promising Vaccine Study

On March 31, 2025, Vaxcyte's stock experienced a significant drop of 13.26% in pre-market trading, indicating a notable shift in investor sentiment towards the biotechnology company.

Vaxcyte's VAX-24 vaccine candidate has shown promising results in an infant vaccine study, meeting the non-inferiority criteria for immune response after a three-dose primary immunization series. This development is crucial as it demonstrates the vaccine's potential to provide effective protection against pneumococcal diseases in infants.

The VAX-24 study is also evaluating the safety and tolerability of the vaccine compared to the existing Prevnar 20. This comparison is essential for understanding how VAX-24 performs in real-world conditions and whether it can offer a viable alternative to current vaccines. The study's focus on healthy infants ensures that the data collected will be relevant to the primary target population for pneumococcal vaccines.